{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:18:01Z","timestamp":1789499881762,"version":"build-2803163510"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"42","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Hubei Provincial Natural Science Foundation of China","award":["No. 2023AFC003."],"award-info":[{"award-number":["No. 2023AFC003."]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,17]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>This case report highlights the diagnostic challenges and clinical complexities of adult-onset pituitary Langerhans Cell Histiocytosis (LCH), a rare entity with a prolonged and indolent progression. This underscores the critical need for heightened clinical suspicion in patients with chronic endocrine dysfunction, particularly in those with multisystem comorbidities. The atypical 10-year diagnostic odyssey coupled with molecular confirmation of the BRAFV600E mutation adds novel insights into delayed recognition and genetic markers in adult LCH, addressing gaps in the existing literature on protracted pituitary involvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 38-year-old woman experienced decade-long polydipsia, polyuria, fatigue, irregular menstruation and progressive panhypopituitarism. Laboratory findings showed hypernatremia (Na 155.7\u2013157.5 mmol\/L), hyperchloremia (Cl 113.6\u2013119.1 mmol\/L), low TSH (0.015\u20130.144 \u00b5IU\/mL) with low-to-normal FT3\/FT4, persistently low cortisol, low FSH\/LH, and low PRL. MRI revealed a 1.9\u2005\u00d7\u20051.4\u2005\u00d7\u20051.2\u2009cm pituitary mass.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnosis:<\/jats:title>\n                    <jats:p>Pituitary LCH was confirmed by nasal saddle area biopsy (S100\/CD1a positivity) and BRAFV600E mutation detection via ARMS-PCR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>Management included desmopressin, glucocorticoid and thyroid hormone replacement, and LCH-III\u2013based chemotherapy with prednisone and vincristine. Mercaptopurine (6-MP) was omitted due to hepatic dysfunction. However, chemotherapy was complicated by hepatic dysfunction, osteoporosis, and type 2 diabetes, which require intermittent cessation of chemotherapy and hepatoprotective therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>Tumor size decreased to 1.0\u2005\u00d7\u20051.2\u2005\u00d7\u20050.7\u2009cm; endocrine deficits persisted, requiring lifelong hormone replacement. The patient\u2019s condition stabilized through continuous multidisciplinary care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>This case emphasizes that chronic endocrine symptoms warrant prompt pituitary imaging and early molecular testing, including BRAFV600E analysis, to avoid prolonged diagnostic delays and enable tailored therapy \u2013 especially in patients with comorbidities limiting standard treatment regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000045274","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:01:05Z","timestamp":1762210865000},"page":"e45274","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Delayed diagnosis of pituitary LCH with BRAFV600E mutation: A case report and literature review"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3248-2363","authenticated-orcid":false,"given":"Yiwei","family":"Hou","sequence":"first","affiliation":[{"name":"The First College of Clinical Medical Science, China Three Gorges University, Yichang, Hubei Province, China"},{"name":"Department of Endocrinology, Yichang Central People\u2019s Hospital, Yichang, Hubei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yang","sequence":"additional","affiliation":[{"name":"The First College of Clinical Medical Science, China Three Gorges University, Yichang, Hubei Province, China"},{"name":"Department of Hepatobiliary Surgery, Yichang Central People\u2019s Hospital, Yichang, Hubei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Liao","sequence":"additional","affiliation":[{"name":"The First College of Clinical Medical Science, China Three Gorges University, Yichang, Hubei Province, China"},{"name":"Department of Oncology, Yichang Central People\u2019s Hospital, Yichang, Hubei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yi","sequence":"additional","affiliation":[{"name":"Medical Technology College of Qiqihar Medical College, Qiqihar, Heilongjiang Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shixin","family":"Li","sequence":"additional","affiliation":[{"name":"The First College of Clinical Medical Science, China Three Gorges University, Yichang, Hubei Province, China"},{"name":"Department of Endocrinology, Yichang Central People\u2019s Hospital, Yichang, Hubei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beihan","family":"Li","sequence":"additional","affiliation":[{"name":"Basic Medical College of Qiqihar Medical University, Qiqihar, Heilongjiang Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxi","family":"Fu","sequence":"additional","affiliation":[{"name":"Medical Technology College of Qiqihar Medical College, Qiqihar, Heilongjiang Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijun","family":"Zhou","sequence":"additional","affiliation":[{"name":"The First College of Clinical Medical Science, China Three Gorges University, Yichang, Hubei Province, China"},{"name":"Department of Endocrinology, Yichang Central People\u2019s Hospital, Yichang, Hubei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxu","family":"Tong","sequence":"additional","affiliation":[{"name":"The First College of Clinical Medical Science, China Three Gorges University, Yichang, Hubei Province, China"},{"name":"Department of Endocrinology, Yichang Central People\u2019s Hospital, Yichang, Hubei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wufei","family":"Zhu","sequence":"additional","affiliation":[{"name":"The First College of Clinical Medical Science, China Three Gorges University, Yichang, Hubei Province, China"},{"name":"Department of Endocrinology, Yichang Central People\u2019s Hospital, Yichang, Hubei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260915","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s12020-014-0408-6","article-title":"The pituitary gland in patients with Langerhans cell histiocytosis: a clinical and radiological evaluation.","volume":"48","author":"Kurtulmus","year":"2015","journal-title":"Endocrine"},{"key":"R2-20260915","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s12020-014-0497-2","article-title":"Langerhans cell histiocytosis and pituitary function.","volume":"48","author":"Makras","year":"2015","journal-title":"Endocrine"},{"key":"R3-20260915","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1056\/NEJMra1607548","article-title":"Langerhans-cell histiocytosis.","volume":"379","author":"Allen","year":"2018","journal-title":"N Engl J Med"},{"key":"R4-20260915","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jaad.2017.05.059","article-title":"Langerhans cell histiocytosis in children: history, classification, pathobiology, clinical manifestations, and prognosis.","volume":"78","author":"Krooks","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"R5-20260915","doi-asserted-by":"crossref","first-page":"532","DOI":"10.2176\/nmc.40.532","article-title":"Langerhans cell histiocytosis limited to the pituitary-hypothalamic axis--two case reports.","volume":"40","author":"Isoo","year":"2000","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"R6-20260915","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1179\/acb.2010.074","article-title":"Langerhans cell histiocytosis: two case reports in adults and review of the literature.","volume":"65","author":"Decoster","year":"2010","journal-title":"Acta Clin Belg"},{"key":"R7-20260915","doi-asserted-by":"crossref","first-page":"e1207","DOI":"10.1111\/j.1741-2358.2012.00629.x","article-title":"Langerhans\u2019s cell histiocytosis in old subjects: two rare case reports and review of the literature.","volume":"29","author":"Lajolo","year":"2012","journal-title":"Gerodontology"},{"key":"R8-20260915","first-page":"59","article-title":"Solitary cranial Langerhans cell histiocytosis: two case reports.","volume":"64","author":"Karki","year":"2015","journal-title":"Hiroshima J Med Sci"},{"key":"R9-20260915","first-page":"e2142","article-title":"Targeted therapy with vemurafenib in brazilian children with refractory Langerhans cell histiocytosis: two case reports and review of literature.","volume":"7","author":"Silva","year":"2024","journal-title":"Cancer Rep (Hoboken)"},{"key":"R10-20260915","first-page":"612","article-title":"Langerhans cell histiocytosis with spinal, pulmonary and pituitary involvement: what about ACTH deficiency without diabetes insipidus? A propos of a case.","volume":"25","author":"Ryan","year":"2020","journal-title":"J BUON"},{"key":"R11-20260915","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s42000-018-0024-6","article-title":"Localised Langerhans cell histiocytosis of the hypothalamic-pituitary region: case report and literature review.","volume":"17","author":"Radojkovic","year":"2018","journal-title":"Hormones (Athens)"},{"key":"R12-20260915","doi-asserted-by":"crossref","first-page":"896227","DOI":"10.3389\/fendo.2022.896227","article-title":"Multi-system Langerhans cell histiocytosis as a mimic of IgG4-related disease: a case report and literature review.","volume":"13","author":"Feng","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R13-20260915","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.14694\/EdBook_AM.2014.34.e441","article-title":"Biological and therapeutic implications of the BRAF pathway in histiocytic disorders.","volume":"34","author":"Arceci","year":"2014","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R14-20260915","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/hon.2344","article-title":"BRAFV600E and MAP2K1 mutations in Langerhans cell histiocytosis occur predominantly in children.","volume":"35","author":"Zeng","year":"2017","journal-title":"Hematol Oncol"},{"key":"R15-20260915","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.3892\/ol.2017.6774","article-title":"Genetic homogeneity of adult Langerhans cell histiocytosis lesions: insights from BRAF(V600E) mutations in adult populations.","volume":"14","author":"Selway","year":"2017","journal-title":"Oncol Lett"},{"key":"R16-20260915","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s12185-021-03205-8","article-title":"Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA.","volume":"114","author":"Evseev","year":"2021","journal-title":"Int J Hematol"},{"key":"R17-20260915","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/onco.13541","article-title":"Efficacy of BRAF-inhibitor therapy in BRAF(V600E) -mutated adult langerhans cell histiocytosis.","volume":"25","author":"Hazim","year":"2020","journal-title":"Oncologist"},{"key":"R18-20260915","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1200\/JCO.19.00456","article-title":"Vemurafenib for refractory multisystem Langerhans cell histiocytosis in children: an international observational study.","volume":"37","author":"Donadieu","year":"2019","journal-title":"J Clin Oncol"},{"key":"R19-20260915","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/2159-8290.CD-15-0913","article-title":"Diverse and targetable kinase alterations drive histiocytic neoplasms.","volume":"6","author":"Diamond","year":"2016","journal-title":"Cancer Discov"},{"key":"R20-20260915","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood-2012-07-446286","article-title":"Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation.","volume":"121","author":"Haroche","year":"2013","journal-title":"Blood"},{"key":"R21-20260915","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1111\/cas.13817","article-title":"Langerhans cell histiocytosis in adults: advances in pathophysiology and treatment.","volume":"109","author":"Kobayashi","year":"2018","journal-title":"Cancer Sci"},{"key":"R22-20260915","doi-asserted-by":"crossref","first-page":"e18761429249717","DOI":"10.2174\/0118761429249717230920113227","article-title":"Regulating miRNAs expression by resveratrol: novel insights based on molecular mechanism and strategies for cancer therapy.","volume":"17","author":"Keshavarzmotamed","year":"2024","journal-title":"Curr Mol Pharmacol"},{"key":"R23-20260915","doi-asserted-by":"crossref","first-page":"e18761429263841","DOI":"10.2174\/0118761429263841230926014118","article-title":"Deregulated MicroRNAs involved in P53 signaling pathway in breast cancer with focus on triple-negative breast cancer.","volume":"17","author":"Naeimzadeh","year":"2024","journal-title":"Curr Mol Pharmacol"},{"key":"R24-20260915","first-page":"10","article-title":"Optimized dynamic network biomarker deciphers a high-resolution heterogeneity within thyroid cancer molecular subtypes.","volume":"1","author":"Zhang","year":"2025","journal-title":"Med Res"},{"key":"R25-20260915","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s00264-008-0529-8","article-title":"Langerhans\u2019 cell histiocytosis of the spine in children with soft tissue extension and chemotherapy.","volume":"33","author":"Peng","year":"2009","journal-title":"Int Orthop"},{"key":"R26-20260915","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1111\/j.1572-0241.2007.01515.x","article-title":"Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients.","volume":"102","author":"Shaye","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"R27-20260915","doi-asserted-by":"crossref","first-page":"1479764","DOI":"10.3389\/fendo.2024.1479764","article-title":"Central and nephrogenic diabetes insipidus: updates on diagnosis and management.","volume":"15","author":"Flynn","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R28-20260915","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1530\/EJE-19-0177","article-title":"Endocrine manifestations in a cohort of 63 adulthood and childhood onset patients with Langerhans cell histiocytosis.","volume":"181","author":"Sagna","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"R29-20260915","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3390\/jcm11040909","article-title":"Adult Langerhans cell histiocytosis and the skeleton.","volume":"11","author":"Georgakopoulou","year":"2022","journal-title":"J Clin Med"},{"key":"R30-20260915","doi-asserted-by":"crossref","first-page":"R246","DOI":"10.1530\/EC-18-0186","article-title":"Bone metabolism in Langerhans cell histiocytosis.","volume":"7","author":"Anastasilakis","year":"2018","journal-title":"Endocr Connect"},{"key":"R31-20260915","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.12688\/f1000research.11948.1","article-title":"Premature ovarian insufficiency - an update on recent advances in understanding and management.","volume":"6","author":"Torrealday","year":"2017","journal-title":"F1000Res"},{"key":"R32-20260915","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/08971900211015046","article-title":"A case-report of drug-induced mixed liver injury resulting from cefepime exposure.","volume":"36","author":"Malhotra","year":"2023","journal-title":"J Pharm Pract"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045274","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:00:13Z","timestamp":1789498813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":32,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045274","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"2025-05-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}